Amarantus BioScience Holdings, Inc. “Q1-2014: The Maturation of Amarantus”

Amarantus Bioscience Holdings, Inc.

(OTCQB:AMBS) published a new blog post on The Chairman’s Blog,

written by the company’s CEO, Gerald Commissiong. is an exclusive online media publication that

provides key executive officers and key opinion leaders a unique

platform to share insights about company and industry trends.


CEO, Gerald Commissiong writes about the implications of being a

small company in the biotech industry. He highlights the recent

progress Amarantus has made, with additions to the management team

and the expansion of the Company’s pipeline. Mr. Commissiong

writes, “For Amarantus, we have taken the view that building a

world-class biotechnology company in the absence of product revenue

(for the time being) requires a number of key elements in order to

truly thrive.” Read about those key elements in his blog post on


About Amarantus

Amarantus is a

biotechnology company developing treatments and diagnostics for

diseases associated with neurodegeneration and protein

misfolding-related apoptosis. The Company has licensed Eltoprazine a

phase 2b ready indication for Parkinson's Levodopa induced

dyskinesia. The Company has an exclusive worldwide license to the

Lymphocyte Proliferation test ("LymPro Test®") for

Alzheimer's disease and owns the intellectual property rights to a

therapeutic protein known as Mesencephalic-Astrocyte-derived

Neurotrophic Factor ("MANF") and is developing MANF-based

products as treatments for brain disorders. Amarantus is a Founding

Member of the Coalition for Concussion Treatment (#C4CT), a movement

initiated in collaboration with Brewer Sports International seeking

to raise awareness of new treatments in development for concussions

and nervous-system disorders. The Company also owns intellectual

property for the diagnosis of Parkinson's disease ("NuroPro")

and the discovery of neurotrophic factors ("PhenoGuard").

For further information please visit,

or connect with the Company on Facebook,



and Google+.

About is

an exclusive, online media publication where publically and

privatively held firms alike share insights about their companies and

industries. enables upper tier management to

discuss issues that are of importance to their stakeholders,

shareholders, and interested parties in an informal environment. In

addition to management`s insightful blog posts,

staff and aggregate partners contribute articles on finance,

technology, health, and energy while providing updated market trends,

news, and information.

Release ID: 34153